We previously reported that the epitope recognized by an influenza A virus H1, H2, and H3-crossreactive, H-2 Ld-restricted CD8+ cytotoxic T lymphocyte (CTL) is located between amino acids 1 and 40 on the nonstructural protein NS1. In the present experiments, we examined whether immunization with recombinant vaccinia virus which contained genes coding for amino acids 1-40 of NS1 (Vac-10) protected mice from lethal challenge with influenza A virus. Mice immunized with this recombinant virus developed influenza A virus-specific cytotoxic activity but not neutralizing antibodies. Challenge with a lethal dose of influenza A virus demonstrated that the first deaths were delayed by 2 days, and the mortality rate was significantly reduced (p \u3c 0...
Recombinant influenza viruses are promising viral platforms to be used as antigen delivery vectors. ...
<div><p>Recombinant influenza viruses are promising viral platforms to be used as antigen delivery v...
Background: Current human influenza vaccines lack the adaptability to match the mutational rate of t...
Influenza viruses with truncated NS1 protein stimulate a more intensive innate immune response compa...
The nucleoprotein (NP) of influenza A virus is the dominant antigen recognized by influenza virus-sp...
The truncation of the nonstructural NS1 protein is a novel approach for the generation of immunogeni...
Since conserved viral proteins of influenza virus, such as nucleoprotein (NP) and matrix 1 protein, ...
We have examined whether active immunization with c13 protein, a hybrid protein of the first 81 amin...
Background: The availability of a universal influenza vaccine able to induce broad cross-reactive im...
The virus-specific cytotoxic T lymphocyte (CTL) induction is an important target for the development...
There is mounting evidence that in the absence of neutralizing antibodies cross-reactive T cells pro...
Recombinant influenza viruses are promising viral platforms to be used as antigen delivery vectors. ...
Hemagglutinin (HA) is the immunodominant protein of the influenza virus. We previously showed that m...
BACKGROUND: The virus-specific cytotoxic T lymphocyte (CTL) induction is an important target for the...
AbstractVaccination is at present the most efficient way of preventing influenza infections. Current...
Recombinant influenza viruses are promising viral platforms to be used as antigen delivery vectors. ...
<div><p>Recombinant influenza viruses are promising viral platforms to be used as antigen delivery v...
Background: Current human influenza vaccines lack the adaptability to match the mutational rate of t...
Influenza viruses with truncated NS1 protein stimulate a more intensive innate immune response compa...
The nucleoprotein (NP) of influenza A virus is the dominant antigen recognized by influenza virus-sp...
The truncation of the nonstructural NS1 protein is a novel approach for the generation of immunogeni...
Since conserved viral proteins of influenza virus, such as nucleoprotein (NP) and matrix 1 protein, ...
We have examined whether active immunization with c13 protein, a hybrid protein of the first 81 amin...
Background: The availability of a universal influenza vaccine able to induce broad cross-reactive im...
The virus-specific cytotoxic T lymphocyte (CTL) induction is an important target for the development...
There is mounting evidence that in the absence of neutralizing antibodies cross-reactive T cells pro...
Recombinant influenza viruses are promising viral platforms to be used as antigen delivery vectors. ...
Hemagglutinin (HA) is the immunodominant protein of the influenza virus. We previously showed that m...
BACKGROUND: The virus-specific cytotoxic T lymphocyte (CTL) induction is an important target for the...
AbstractVaccination is at present the most efficient way of preventing influenza infections. Current...
Recombinant influenza viruses are promising viral platforms to be used as antigen delivery vectors. ...
<div><p>Recombinant influenza viruses are promising viral platforms to be used as antigen delivery v...
Background: Current human influenza vaccines lack the adaptability to match the mutational rate of t...